journal
MENU ▼
Read by QxMD icon Read
search

Journal of Thrombosis and Thrombolysis

journal
https://www.readbyqxmd.com/read/28229274/oral-antiplatelet-drugs-in-patients-with-chronic-kidney-disease-ckd-a-review
#1
REVIEW
Homam Ibrahim, Sunil V Rao
Oral Antiplatelet Drugs (OAD) have a proven track record in the risk reduction of major cardiovascular events in patients with cardiovascular disease and normal kidney function. However, major gaps exist in our understanding of their effects on thrombosis and bleeding in chronic kidney disease (CKD). Clinical practice guidelines are ambiguous about use of such drugs in CKD patients, because patients with moderate to severe CKD were systematically excluded from clinical trials evaluating the efficacy and safety of OAD...
February 22, 2017: Journal of Thrombosis and Thrombolysis
https://www.readbyqxmd.com/read/28220330/synchronous-cardiocerebral-infarction-in-the-era-of-endovascular-therapy-which-to-treat-first
#2
Leonard L L Yeo, Tommy Andersson, Kong Wan Yee, Benjamin Y Q Tan, Prakash Paliwal, Anil Gopinathan, Mahendran Nadarajah, Eric Ting, Hock L Teoh, Robin Cherian, Erik Lundström, Edgar L W Tay, Vijay K Sharma
A cardiocerebral ischemic attack (CCI) or a concurrent acute ischemic stroke (AIS) and myocardial infarction (AMI) is a severe event with no clear recommendations for ideal management because of the rarity of the scenario. The narrow time window for treatment and complexity of the treatment decision puts immense pressure on the treating physician. We evaluated this challenging situation at our tertiary center. Using our prospective stroke database out of a total of 555 patients with acute ischemic stroke between 2009 and 2014, we identified five consecutive cases with CCI (incidence 0...
February 20, 2017: Journal of Thrombosis and Thrombolysis
https://www.readbyqxmd.com/read/28220329/disproportional-increase-of-pulmonary-embolism-in-young-females-in-germany-trends-from-2005-to-2014
#3
F Santosa, Ch Moerchel, Ch Berg, K Kröger
We analysed the number of pulmonary embolism (PE) in young females aged 10-39 years in the period from 2005 to 2014 in Germany to see any trends that possibly may reflect some influences of newer oral contraceptives. Detailed lists of all hospitalized cases with the principal diagnosis PE coded as I26 in the years 2005-2014 were provided by the Federal Statistical Office. In males, the absolute number of all hospitalized cases with the principal diagnosis PE increased from 16,066 in 2005 to 25,364 in 2014 (rate +57...
February 20, 2017: Journal of Thrombosis and Thrombolysis
https://www.readbyqxmd.com/read/28214949/intravenous-thrombolysis-for-stroke-after-dabigatran-reversal-with-idarucizumab-an-update
#4
LETTER
Manuel Cappellari, Stefano Forlivesi, Giovanna Maddalena Squintani, Roberto Facchinetti, Paolo Bovi
No abstract text is available yet for this article.
February 18, 2017: Journal of Thrombosis and Thrombolysis
https://www.readbyqxmd.com/read/28214948/reduced-anticoagulation-variability-in-patients-on-warfarin-monitored-with-fiix-prothrombin-time-associates-with-reduced-thromboembolism-the-fiix-trial
#5
Alma Rut Oskarsdóttir, Brynja R Gudmundsdottir, Olafur S Indridason, Sigrun H Lund, David O Arnar, Einar S Bjornsson, Magnus K Magnusson, Hulda M Jensdottir, Brynjar Vidarsson, Charles W Francis, Pall T Onundarson
Fiix-prothrombin time (Fiix-PT) differs from traditional PT in being affected by reduced factor (F) II or FX only. In the randomized controlled Fiix-trial, patients on warfarin monitored with Fiix-PT (Fiix-warfarin patients) had fewer thromboembolisms (TE), similar major bleeding (MB) and more stable anticoagulation than patients monitored with PT (PT-warfarin patients). In the current Fiix-trial report we analyzed how reduced anticoagulation variability during Fiix-PT monitoring was reflected in patients with TE or bleeding...
February 18, 2017: Journal of Thrombosis and Thrombolysis
https://www.readbyqxmd.com/read/28210989/net-clinical-benefit-of-dabigatran-vs-warfarin-in-venous-thromboembolism-analyses-from-re-cover-%C3%A2-re-cover%C3%A2-ii-and-re-medy%C3%A2
#6
Martin Feuring, Sam Schulman, Henry Eriksson, Ajay J Kakkar, Sebastian Schellong, Stefan Hantel, Elke Schueler, Jörg Kreuzer, Samuel Z Goldhaber
The direct oral anticoagulants, e.g., dabigatran etexilate (DE), are effective and well tolerated treatments for venous thromboembolism (VTE). Net clinical benefit (NCB) is a useful concept in weighing potential benefits against potential harm of comparator drugs. The NCB of DE vs. warfarin in VTE treatment was compared. Post-hoc analyses were performed on pooled data from the 6-month RE-COVER® and RE-COVER™ II trials, and data from the RE-MEDY™ trial (up to 36 months), to compare the NCB of DE (150 mg twice daily) and warfarin [target international normalized ratio (INR) 2...
February 16, 2017: Journal of Thrombosis and Thrombolysis
https://www.readbyqxmd.com/read/28210988/real-life-experience-with-the-specific-reversal-agent-idarucizumab-for-the-management-of-emergency-situations-in-dabigatran-treated-patients-a-series-of-11-cases
#7
Milan R Vosko, Christof Bocksrucker, Rafał Drwiła, Petr Dulíček, Tomas Hauer, Johannes Mutzenbach, Christoph J Schlimp, David Špinler, Thomas Wolf, Daša Zugwitz
Non-vitamin K antagonist oral anticoagulants (NOACs) have a favorable benefit-risk profile compared with vitamin K antagonists. However, the lack of specific reversal agents has made the management of some patients receiving long-term treatment with NOACs problematic in emergency situations such as major bleeding events or urgent procedures. Idarucizumab, a fully humanized Fab antibody fragment that binds specifically and with high affinity to dabigatran, was recently approved for use in adult patients treated with dabigatran when rapid reversal of its anticoagulant effect is required...
February 16, 2017: Journal of Thrombosis and Thrombolysis
https://www.readbyqxmd.com/read/28205078/enoxaparin-dose-reduction-for-thrombocytopenia-in-patients-with-cancer-a-quality-assessment-study
#8
Simon Mantha, Yimei Miao, Jonathan Wills, Rekha Parameswaran, Gerald A Soff
The development of thrombocytopenia in the setting of therapeutic anticoagulation for venous thromboembolic disease (VTE) is common in cancer patients, but guidelines for management are based on limited past data and have not been validated. In 2011, Memorial Sloan Kettering Cancer Center (MSKCC) implemented the following guidelines in this setting: administer full dose enoxaparin for a platelet count > 50,000/mcL, half-dose enoxaparin for a platelet count of 25,000-50,000/mcL, and hold anticoagulation for a platelet count < 25,000/mcL...
February 16, 2017: Journal of Thrombosis and Thrombolysis
https://www.readbyqxmd.com/read/28197755/direct-oral-anticoagulants-for-extended-duration-thromboprophylaxis-in-hospitalized-medically-ill-patients-are-we-there-yet
#9
Majed S Al Yami, Osamah M Alfayez, Sawsan M Kurdi, Razan Alsheikh
Despite a recommended 7-10 days of thromboprophylaxis, medically ill patients remain at increased risk of developing venous thromboembolism (VTE) after hospital discharge. Here, we present a contemporary review on the efficacy and safety of extended-duration thromboprophylaxis with direct oral anticoagulants (DOACs) in hospitalized medically ill patients. A search of publication and trial databases of controlled trials conducted from 2010 to 2016 using the key terms apixaban, rivaroxaban, and betrixaban showed three phase III trials that met our search criteria...
February 14, 2017: Journal of Thrombosis and Thrombolysis
https://www.readbyqxmd.com/read/28194628/association-between-ck-mb-area-under-the-curve-and-tranexamic-acid-utilization-in-patients-undergoing-coronary-artery-bypass-surgery
#10
Sean van Diepen, Peter D Merrill, Michel Carrier, Jean-Claude Tardif, Mihai Podgoreanu, John H Alexander, Renato D Lopes
Myonecrosis after coronary artery bypass graft (CABG) surgery is associated with excess mortality. Tranexamic acid (TA), an anti-fibrinolytic agent, has been shown to reduce peri-operative blood loss without increasing the risk of myocardial infarction (MI); however, no large study has examined the association between TA treatment and post-CABG myonecrosis. In the MC-1 to Eliminate Necrosis and Damage in Coronary Artery Bypass Graft Surgery II trial, inverse probability weighting of the propensity to receive TA was used to test for differences among the 656 patients receiving and 770 patients not receiving TA...
February 14, 2017: Journal of Thrombosis and Thrombolysis
https://www.readbyqxmd.com/read/28168541/early-use-of-direct-oral-anticoagulants-after-tia-stroke-in-patients-with-atrial-fibrillation-a-2016-update
#11
LETTER
Manuel Cappellari, Paolo Bovi
No abstract text is available yet for this article.
February 6, 2017: Journal of Thrombosis and Thrombolysis
https://www.readbyqxmd.com/read/28138812/trends-in-oral-anticoagulant-use-in-qatar-a-5-year-experience
#12
Hazem Elewa, Amani Alhaddad, Safa Al-Rawi, Amir Nounou, Hesham Mahmoud, Rajvir Singh
In Qatar, dabigatran was introduced in 2011 followed by rivaroxaban in 2014. In this study, we aim to explore the trends in oral anticoagulant use in Qatar over the past 5 years and to what extent did DOACs replace warfarin. We also explored the extent of switching between different anticoagulants (from warfarin to DOACs and vice versa). We collected all anticoagulant prescriptions dispensed as in- or out-patient from 2011 to 2015 in all Hamad Medical Corporation (HMC) hospitals. Overall number of patients using warfarin, dabigatran and rivaroxaban over the last 5 years collectively was calculated...
January 30, 2017: Journal of Thrombosis and Thrombolysis
https://www.readbyqxmd.com/read/28102475/prospective-evaluation-of-a-bivalirudin-to-warfarin-transition-nomogram
#13
Benjamin Hohlfelder, Katelyn W Sylvester, Jessica Rimsans, David DeiCicchi, Jean M Connors
Bivalirudin may cause a falsely prolonged international normalized ratio (INR) that complicates the discontinuation of bivalirudin when used as a bridge to warfarin. To prospectively validate our novel bivalirudin to warfarin transition nomogram, adult patients who received bivalirudin as a bridge to warfarin between July 2015 and June 2016 were prospectively evaluated, utilizing our predictive nomogram. The major outcome of our analysis was the correlation between the predicted change in INR upon bivalirudin discontinuation based on the nomogram, and the actual change in INR upon bivalirudin discontinuation...
January 19, 2017: Journal of Thrombosis and Thrombolysis
https://www.readbyqxmd.com/read/28101716/circulating-activated-protein-c-in-thrombophilia-carriers
#14
LETTER
Thijs E van Mens, Joost C M Meijers, Saskia Middeldorp
No abstract text is available yet for this article.
January 18, 2017: Journal of Thrombosis and Thrombolysis
https://www.readbyqxmd.com/read/28093650/diabetes-mellitus-is-associated-with-increased-bleeding-in-pulmonary-embolism-receiving-conventional-anticoagulant-therapy-findings-from-a-real-world-study
#15
Zhu Zhang, Zhenguo Zhai, Yuanhua Yang, Jun Wan, Wanmu Xie, Jianguo Zhu, Ying H Shen, Chen Wang
Bleeding refers to the most important complication during anticoagulation therapy in patients with pulmonary embolism (PE). However, the incidence and risk factors of bleeding in Chinese population with anticoagulant therapy remains unknown. Although diabetes mellitus (DM) has been demonstrated to increase the risk of PE, little information of its influence on anticoagulation-associated bleeding risk can be available. In our study, 563 acute PE patients, who fulfilled the including criteria were enrolled from a single center and received conventional anticoagulant therapy...
January 16, 2017: Journal of Thrombosis and Thrombolysis
https://www.readbyqxmd.com/read/28074413/procoagulant-activity-of-extracellular-vesicles-as-a-potential-biomarker-for-risk-of-thrombosis-and-dic-in-patients-with-acute-leukaemia
#16
Damien Gheldof, Hélène Haguet, Jean-Michel Dogné, Céline Bouvy, Carlos Graux, Fabienne George, Anne Sonet, Christian Chatelain, Bernard Chatelain, François Mullier
Haemostatic complication is common for patients with hematologic malignancies. Recent studies suggest that the procoagulant activity (PCA) of extracellular vesicles (EV) may play a major role in venous thromboembolism and disseminated intravascular coagulation (DIC) in acute leukaemia. To study the impact of EVs from leukaemic patients on thrombin generation and to assess EV-PCA as a potential biomarker for thrombotic complications in patients with acute leukaemia. Blood samples from a cohort of patients with newly diagnosed acute leukaemia were obtained before treatment (D-0), 3 and 7 days after treatment (D-3 and D-7)...
January 10, 2017: Journal of Thrombosis and Thrombolysis
https://www.readbyqxmd.com/read/28070821/evaluation-of-safety-and-effectiveness-of-standardized-antifactor-xa-based-unfractionated-heparin-protocols-in-obese-versus-non-obese-patients
#17
Manuel Isherwood, Michelle L Murphy, Angela L Bingham, Laura A Siemianowski, Krystal Hunter, James M Hollands
Recent data have suggested that standard unfractionated heparin (UFH) protocols may over-anticoagulate obese patients. The goal of this retrospective study was to observe differences in anticoagulation parameters and safety outcomes for standardized antifactor Xa UFH protocols in obese and non-obese populations. Obese patients (N = 148) were identified over a 20-month period and matched to 148 non-obese patients based on age, gender, and admission date. Patients were included if they were on one of three approved UFH protocols [high (target antifactor Xa 0...
January 9, 2017: Journal of Thrombosis and Thrombolysis
https://www.readbyqxmd.com/read/28070820/development-of-a-new-catheter-prototype-for-laser-thrombolysis-under-guidance-of-optical-coherence-tomography-oct-validation-of-feasibility-and-efficacy-in-a-preclinical-model
#18
Rouven Berndt, Rene Rusch, Lars Hummitzsch, Matthias Lutz, Katharina Heß, Katharina Huenges, Bernd Panholzer, Christoph Otte, Assad Haneya, Georg Lutter, Alexander Schlaefer, Jochen Cremer, Justus Groß
In this feasibility study, a novel catheter prototype for laser thrombolysis under the guidance of optical coherence tomography (OCT) was designed and evaluated in a preclinical model. Human arteries and veins were integrated into a physiological flow model and occluded with thrombi made from the Chandler Loop. There were four experimental groups: placebo, 20 mg alteplase, laser, 20 mg alteplase + laser. The extent of thrombolysis was analyzed by weighing, OCT imaging and relative thrombus size. In the alteplase group, thrombus size decreased to 0...
January 9, 2017: Journal of Thrombosis and Thrombolysis
https://www.readbyqxmd.com/read/28063132/evaluation-of-role-of-fv-fviii-and-aplas-in-the-pathogenesis-of-apcr-in-fv-leiden-negative-dvt-patients-a-study-in-india
#19
Amit Sharma, Kanwaljeet Singh, Arijit Biswas, Ravi Ranjan, Kamal Kishor, Ravi Kumar, Hareram Pandey, Vineet Kumar Kamal, Renu Saxena
Resistance to APC (APCR) is a very important cause of thrombophilia and most frequently caused by the Leiden mutation. APCR is also seen in the absence of FV Leiden and associated with elevated levels of factor V (FV), factor VIII (FVIII) and antiphospholipid antibodies (APLAs). The aim of this prospective case control study was to find out the frequency and role of FV, FVIII and APLAs in the pathogenesis of APCR in FV Leiden negative deep vein thrombosis (DVT) patients in India. A total 30 APCR positive and FV Leiden negative patients with DVT and similar number of age and sex matched healthy controls were recruited...
January 6, 2017: Journal of Thrombosis and Thrombolysis
https://www.readbyqxmd.com/read/28054307/etiology-and-complications-of-thrombocytopenia-in-hospitalized-medical-patients
#20
Eric M Fountain, Gowthami M Arepally
To determine incidence, risk factors, hematologic complications, and prognostic significance of thrombocytopenia in the general medicine population, we performed a single-institutional, retrospective study of all adult patients admitted to a general medical ward from January 1st, 2014 to December 31st, 2014 with hospital-acquired thrombocytopenia. Those with moderate thrombocytopenia, defined as a platelet count nadir of <100 × 10^9/L and/or a >50% relative decline, were compared to those with less severe thrombocytopenia...
January 4, 2017: Journal of Thrombosis and Thrombolysis
journal
journal
32163
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"